Drugs / MK-1697
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03515824 | Aug 2018 → Feb 2020 | colorectal neoplasm, head and neck neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1697 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03515824 ↗ |
| Route | Intravenous | “by IV infusion” NCT03515824 ↗ |